Pacira | PCRX - Interest Expense On Debt


Pacira reported $4.28M in Interest Expense on Debt for its fiscal quarter ending in September of 2025.





Interest Expense On Debt Change Date
Assertio Holdings USD 758K 1000 Jun/2024
Astellas Pharma JPY 3.91B 320M Mar/2025
Bristol-Myers Squibb USD 432M 48M Dec/2025
Cara Therapeutics 43.75M 4.8M Jun/2025
Coherus Biosciences USD 2.15M 3.2M Mar/2025
Heron Therapeutics USD 500K 900K Sep/2024
Ironwood Pharmaceuticals USD 8.74M 506K Dec/2024
J&J USD 18M 290M Sep/2025
Ligand Pharmaceuticals USD 910K 243K Sep/2025
Nektar Therapeutics USD 6.02M 420K Sep/2024
Novo Nordisk DKK 1.53B 3.43B Sep/2025
Omeros USD 4.05M 5.16M Sep/2024
Pacira USD 4.28M 456K Sep/2025
Perrigo USD 10.08B 10.04B Sep/2025
Pfizer USD 711M 59M Dec/2025
Supernus Pharmaceuticals USD 910K 278K Jun/2023
Teva Pharmaceutical Industries USD 220M 17M Dec/2025
Xeris Pharmaceuticals USD 7.27M 92K Sep/2025
Xoma USD 3.4M 150K Jun/2024
Zoetis USD 57M 1000K Dec/2025